1 / 6

HPV Vaccine Update A new tool for preventing cervical cancer

HPV Vaccine Update A new tool for preventing cervical cancer. Heather M. Brandt, PhD, CHES University of South Carolina Cancer Prevention and Control Program Email: hbrandt@sc.edu Tel: 803.734.4428 South Carolina Cancer Alliance Quarterly Meeting July 13, 2006. HPV Vaccines.

astin
Download Presentation

HPV Vaccine Update A new tool for preventing cervical cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HPV Vaccine UpdateA new tool for preventing cervical cancer Heather M. Brandt, PhD, CHES University of South Carolina Cancer Prevention and Control Program Email: hbrandt@sc.edu Tel: 803.734.4428 South Carolina Cancer Alliance Quarterly Meeting July 13, 2006

  2. HPV Vaccines • Result of scientific discoveries and emerging technology • Prevention-oriented (currently) • Therapeutic vaccines in the future • Two HPV vaccines: • GARDASIL® (Merck & Co.) [recently approved by US FDA] • CERVARIX™ (GlaxoSmithKline) • Will not replace cervical cancer screening (but will likely change it)

  3. GARDASIL® Merck & Co. • Preventive vaccine • Given before sexually active • Four types of genital HPV infection: • High-risk (oncogenic) types 16, 18 • Present in ~75% of cervical cancer cases • Low-risk (non-oncogenic) types 6, 11 • Cause ~90% of genital warts cases

  4. GARDASIL® Merck & Co. • Virus-like particles – “copycat” or “look like” HPV types • Three administrations (0, 2, 6 months) • 100% effective in short-term cervical cancer outcomes • Duration of protection has not been established • Cost is about $120 per dose (~$360 total)

  5. GARDASIL® Merck & Co. • U.S. FDA approved GARDASIL® • Issued licensure agreement (i.e., “label”) • Label is for 9-26 year old females • Advisory Committee on Immunization Practices issued recommendations • 11-12 year old females • Females as early as age 9 and “catch up” vaccinations for females age 13-26

  6. HPV Vaccines • For more information… Centers for Disease Control and Prevention 1-800-458-5231 www.cdc.gov/std/hpv/default.htm National Cancer Institute 1-800-4-CANCER (1-800-422-6237) www.cancer.gov/cancertopics/understandingcancer/HPV-vaccine

More Related